Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.74 |
| ▸ | POLB | P06746 | 1/20 | 0.74 |
| ▸ | TRPV1 | Q8NER1 | 9/20 | 0.66 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.66 |
| ▸ | MEN1 | O00255 | 3/20 | 0.65 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.65 |
| ▸ | MPO | P05164 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | HTR1A | P08908 | 1/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | NQO2 | P16083 | 1/20 | 0.65 |
| ▸ | HTR2B | P41595 | 1/20 | 0.65 |
| ▸ | RAB9A | P51151 | 1/20 | 0.65 |
| ▸ | BLM | P54132 | 1/20 | 0.65 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6919747 | 0.83 | TRPV1 (0.88) | KMT2APOLBTRPV1MTNR1AMEN1 | |
| SCHEMBL5209374 | 0.83 | SMN1; SMN2 (0.71) | KMT2APOLBTRPV1MEN1ALDH1A1 | |
| SCHEMBL32678271 | 0.81 | TRPV1 (0.70) | KMT2APOLBTRPV1MTNR1AMEN1 | |
| SCHEMBL32678273 | 0.81 | TRPV1 (0.70) | KMT2APOLBTRPV1MTNR1AMEN1 | |
| SCHEMBL28663007 | 0.81 | KMT2A (0.87) | KMT2APOLBTRPV1MTNR1AMEN1 | |
| SCHEMBL798092 | 0.81 | KMT2A (0.80) | KMT2APOLBTRPV1MTNR1AMEN1 | |
| SCHEMBL32678333 | 0.81 | KMT2A (0.60) | KMT2APOLBTRPV1MTNR1AMEN1 | |
| SCHEMBL26434358 | 0.81 | KMT2A (0.69) | KMT2APOLBTRPV1MTNR1AMEN1 | |
| SCHEMBL9936354 | 0.80 | TRPV1 (1.00) | KMT2APOLBTRPV1MTNR1AMEN1 | |
| SCHEMBL23644935 | 0.79 | MTNR1A (0.83) | KMT2APOLBTRPV1MTNR1AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1362033-B1 | PYRIDINE MATRIX METALLOPROTEINASE INHIBITORS | WARNER LAMBERT CO (US) | 2007-04-04 | — | — | EP | claimed |
| EP-1362033-A1 | PYRIDINE MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2003-11-19 | — | — | EP | claimed |
| US-20020161000-A1 | Pyridine matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY | 2002-10-31 | — | — | US | claimed |
| WO-2002064568-A1 | PYRIDINE MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | claimed |
| EP-1362033-B1 | PYRIDINE MATRIX METALLOPROTEINASE INHIBITORS | WARNER LAMBERT CO (US) | 2007-04-04 | — | — | EP | disclosed |
| US-7015237-B2 | Pyridine matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2006-03-21 | — | — | US | disclosed |
| US-6881743-B2 | Pyridine matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-04-19 | — | — | US | disclosed |
| US-20040209922-A1 | Pyridine matrix metalloproteinase inhibitors | BARVIAN NICOLE CHANTEL (US) | 2004-10-21 | — | — | US | disclosed |
| US-20040019054-A1 | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib | ROARK WILLIAM HOWARD (US) | 2004-01-29 | — | — | US | disclosed |
| EP-1362033-A1 | PYRIDINE MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2003-11-19 | — | — | EP | disclosed |
| US-20020161000-A1 | Pyridine matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY | 2002-10-31 | — | — | US | disclosed |
| WO-2002064568-A1 | PYRIDINE MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209922-A1 | Pyridine matrix metalloproteinase inhibitors | MMP13, MMP3, MMP11 | KMT2A 1786/4885POLB 2373/4885TRPV1 3231/4885 |
| US-20020161000-A1 | Pyridine matrix metalloproteinase inhibitors | MMP13, MMP3, MMP11 | KMT2A 1722/4885POLB 2459/4885TRPV1 3214/4885 |
| US-20040019054-A1 | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib | MMP13, MMP11, MMP10 | KMT2A 1331/4885POLB 2804/4885TRPV1 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.